Indaptus Therapeutics (INDP) logo

Indaptus Therapeutics (INDP) stock

Worth $376MShares as of Aug 13

$2.82
-9.90%

Not scored

Breakaway doesn't score INDP. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Cash$11.6M, about 3 quarters at the last year's spendingOn Jun 30 · raised money since, not counted

Follow INDP's trial news. Pro members can get an alert when Indaptus Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when INDP files news on its trialSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. 3,170 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$11.6M, about 3 quarters at the last year's spendingOn Jun 30 · raised money since, not counted

What's next for INDP, and how long its cash lasts

Its trials

A trial underway
DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsPhase 1/2 · Active · 120 people · main data estimated Jun 30, 2027 · NCT05651022

For Pro members: 47 filings.

Cash runway Jun 30 balance sheet

About 3 quarters

$11.6M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Aug 13, 2025)
  • At-the-market share sales program (424B5, filed Aug 31, 2026)

For Pro members: 6 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Junyi Dai’s 2 filings and quotes.

Get an alert when INDP files news on its trialA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

INDP's latest filings

36 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why INDP isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. INDP trades about 225,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See every stock rankedSee every stock rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The price on this page is delayed at least 15 minutes.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.